Trial
NCT03597009
A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
UNC Lineberger Comprehensive Cancer Center
Collaborators
C. R. Bard; Amgen
Condition
Malignant Pleural Effusion
Intervention
Talimogene laherparepvec (TVEC)
Why stopped
due to slow accrual and withdrawal of funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-04-20